DDInter1024 DDInter704
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Lapatinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Lapatinib {u} (Compound) upregulates {v} (Gene) BAMBI
BAMBI {u} (Gene) is upregulated by {v} (Compound) Everolimus
Lapatinib {u} (Compound) downregulates {v} (Gene) PTPN1
PTPN1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Lapatinib {u} (Compound) binds {v} (Gene) ERBB2
ERBB2 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Lapatinib {u} (Compound) upregulates {v} (Gene) PSMB8
PSMB8 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Lapatinib {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Lapatinib {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Everolimus
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Lapatinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Lapatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Lapatinib (Compound) upregulates BAMBI (Gene) and BAMBI (Gene) is upregulated by Everolimus (Compound)
Lapatinib (Compound) downregulates PTPN1 (Gene) and PTPN1 (Gene) is upregulated by Everolimus (Compound)
Lapatinib (Compound) binds ERBB2 (Gene) and ERBB2 (Gene) is downregulated by Everolimus (Compound)
Lapatinib (Compound) upregulates PSMB8 (Gene) and PSMB8 (Gene) is downregulated by Everolimus (Compound)
Lapatinib (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Everolimus (Compound)
Lapatinib (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Everolimus (Compound)
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Lapatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)